Results 141 to 150 of about 97,035 (258)
Concomitant activation of D<sub>1</sub> dopamine and α<sub>2A</sub> adrenergic receptors improves cognition better than methylphenidate in two rodent behavioral tests. [PDF]
Bransom L +4 more
europepmc +1 more source
Novel approaches for drug development against chronic primary pain: A systematic review
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus +5 more
wiley +1 more source
Activation of α2-adrenergic receptors as a therapeutic strategy for immune rejection in post-surgery osteosarcoma recurrence treatment. [PDF]
Pei YH +11 more
europepmc +1 more source
Abstract Background and Purpose Chemotherapy‐induced peripheral neuropathy (CIPN) is a prevalent and treatment‐resistant side effect of platinum‐based chemotherapy, characterised by mechanical allodynia. Cannabigerol (CBG), a non‐psychoactive cannabinoid, has shown antinociceptive potential, but its site and mechanism of action remain unclear.
Quinn W. Wade +7 more
wiley +1 more source
Central injection of epidermal growth factor (EGF) induces hypophagia via D₁ dopaminergic and β₂ adrenergic receptors in broiler chickens. [PDF]
Jafari-Ardakan Z +2 more
europepmc +1 more source
Cancer pain: current practice and emerging targets
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye +5 more
wiley +1 more source
Distinct functions of cardiac β-adrenergic receptors in the T-tubule vs<i>.</i> outer surface membrane. [PDF]
Madders GWP +12 more
europepmc +1 more source
Cardiotoxicity of BRAF/MEK inhibitors
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe +4 more
wiley +1 more source

